Lutetium-177 (¹⁷⁷Lu) a high-energy, medium-range beta-emitting radioactive isotope that serves as the global gold standard for targeted radionuclide therapy in precision oncology. It functions by releasing localized, tissue-destroying beta radiation directly into cancer cells, while simultaneously emitting low-energy gamma rays that allow to image and track the tumors.
Main Medical and Clinical Uses Lutetium-177 is uniquely paired with specialized targeting molecules (peptides or antibodies) that act as "homing devices" to deliver cytotoxic radiation directly to specific tumor biomarkers, a clinical approach known as theranostics.
Metastatic Prostate Cancer Treatment:
It targets the Prostate-Specific Membrane Antigen protein heavily expressed on advanced prostate cancer cells. Used for patients with metastatic castration-resistant prostate cancer who have already progressed through chemotherapy.
Neuroendocrine Tumor Therapy:
Targets somatostatin receptors on gastroenteropancreatic neuroendocrine tumors.
Theranostic Imaging:
As it destroys cancer cells via beta decay, ¹⁷⁷Lu simultaneously emits gamma photons. This allows to perform Single-Photon Emission Computed Tomography scans to visualize exactly where the drug has localized in the patient's body and calculate precise internal radiation doses.
Clinical Advantages
Short Radiation Range:
Its beta particles have a maximum tissue penetration depth of only 2 mm. This tight radius limits collateral radiation damage to surrounding healthy tissue, such as vital bone marrow.
Optimal Half-Life:
Its half-life of 6.734 days provides a perfect logistical window. It is long enough for manufacturing and global shipping, yet short enough to decay quickly within the patient's body after delivering the therapeutic payload.
Method of production:
No-Carrier-Added (n.c.a. ¹⁷⁷Lu): This method yields maximum radiochemical purity, contains no long-lived radioactive impurities
Essential Safety & Handling Protocol Because ¹⁷⁷Lu is a potent radioactive material, medical staff must adhere to stringent nuclear regulatory standards:
Shielding: Use lead shielding, such as vial and syringe shields, to effectively block both therapeutic beta emissions and the associated gamma photons.
Contamination Control: Administer the drug through closed, automated infusion loops to prevent skin contamination or accidental spill exposure to healthcare workers.
Excreta Management: Patients remain radioactive for several days post-infusion. To protect family members and the public, strict radiation safety precautions must be taken when handling their bodily fluids (primarily urine).
